The Asia pacific biopharma excipients market size was USD 652.98 Million in 2022 and is likely to reach USD 1.16 Billion by 2031, expanding at a CAGR of 6.63% during 2023–2031. The growth of the market is attributed to the increasing biosimilar R&D investments and the patent expiry of top-selling biologics.
Active pharmaceutical ingredients (APIs) and inactive components (excipients) are both included in pharmaceutical raw materials. Excipients are pharmacologically inactive substances that are commonly used as a carrier of the API in the drug. APIs are bulk drugs that are pharmaceutically active and generate a desired pharmacological effect, whereas excipients are pharmacologically inactive substances that are generally used as a carrier of the API in the drug.
Excipients provide formulations bulkiness, aid in medication absorption, maintain drug stability, and prevent denaturation. Pharmaceutical excipients are low-cost, stable, easy-to-handle, and chemically inert. Excipients are found in a wide range of pharmaceutical products, including capsules, tablets, oral liquids, inhalers, implants, and injections. Without a proper delivery mechanism, even the finest new therapeutic entity in the world is worthless.
Biopharmaceutical excipients are compounds that are used in pharmaceutical dosage forms to help with the manufacturing process, to protect, support, or increase stability, or to improve bioavailability or patient acceptability. It is also used to change the color, binding ability, taste, elegancy, and release rate of the active pharmaceutical ingredient depending on the need. Excipients are commonly used as binding agents, co-processed excipients, emulsifier agents, carrier agents, diluent excipients, and other stabilizing compounds.
Market Trends, Drivers, Restraints, and Opportunities
Increasing prevalence of chronic diseases in the region is anticipated to boost the market growth during the forecast period.
Increasing geriatric population, changing lifestyle in Asia pacific region are estimated to drive the market growth in the coming years.
Increasing demand for generics coupled with favorable initiatives by government and non-government bodies are main factors fueling the market growth during the forecast period.
Technological advancements such as the adoption of nanotechnology in the development of novel compounds to improve medication delivery is expected to spur the market growth.
High capital investments and time-intensive drug development process possess as key challenges that can hamper the market growth during the forecast period.
Increasing emphasis on the rapid development of COVID-19 vaccines and therapeutic drugs is anticipated to boost the market growth in the coming years.
Key players in the market are planning for expansion in emerging economies such as China and India are anticipated to offer lucrative opportunities for the market players.
Increasing development in pharmaceutical industry and increased R&D initiatives are estimated to fuel the market growth during the forecast period.
Scope of the Report
The report on the Asia pacific biopharma excipients market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Biopharma Excipients Market - Asia Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast
Product (Solubilizers & Surfactants/Emulsifiers [Triglycerides, Esters, and Others], Polyols [Mannitol, Sorbitol, and Others], Carbohydrates [Sucrose, Dextrose, Starch, and Others], and Specialty Biopharma Excipients/ Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Signet Chemical Corporation Pvt. Ltd.; ABITEC; Sigachi Industries Pvt. Ltd.; Roquette; Colorcon; Meggle AG; Clariant; DFE Pharma; SPI Pharma; IMCD; Spectrum Chemical Manufacturing Corp.; Pharmonix; BASF SE.
Market Segment Insights
Carbohydrates segment is expected to account for a key share
Based on product, the Asia pacific biopharma excipients market is segmented into solubilizers & surfactants/emulsifiers, polyols, carbohydrates, and specialty Biopharma Excipients/ Others. The solubilizers & surfactants/emulsifiers segment is further bifurcated into triglycerides, esters, and others. The polyols segment is further sub segmented into mannitol, sorbitol, and others.
The carbohydrates segment is further sub segmented into sucrose, dextrose, starch, and others. The carbohydrates segment is expected to account for a key share of the market during the forecast period owing to availability of wide range of products. Manufacturers can increase the required characteristics of these molecules for usage with bioactive compounds due to technological advancements.
Due to potential to boost final product yield, stabilize different biologics, avoid aggregation, and improve the whole process of biopharmaceutical production, high purity carbohydrates such as trehalose are being increasingly used in the development of biosimilars. Dextrose, sucrose, and starch are the three most frequent carbohydrates utilized to stabilize proteins. Trehalose, maltose, galactose, and mannose are among the carbohydrate excipients.
On the other hand, the polyols segment is anticipated to expand at a rapid pace during the forecast period due to increased usage as isotonicity agents and stabilizers in both lyophilized and liquid formulations. To prevent aggregation and degradation, most biomolecule-based treatments are lyophilized. One or the other polyol is used in all lyophilized formulations. The most often utilized polyols are sorbitol (polysorbate 80 and polysorbate 20) and mannitol.
Asia pacific biopharma excipients market is anticipated to expand
Asia pacific biopharma excipients market is anticipated to expand at an impressive CAGR during the forecast period. Japan led the Asia Pacific biopharma excipients market due to greater products sold at a higher price. Because of greater products sold at a higher price, Japan led the Asia Pacific biopharma excipients market.
The growing number of contract research organizations (CROs) in the country that assist multinational firms with biopharmaceutical research and approval is also contributing to the market's growth. However, owing to a smaller percentage of biopharmaceuticals, Japan's pharmaceutical sector is expected to suffer a drop, which, if the trend continues, would likely limit revenue creation in the Japan market.
On the other hand, India is expected to exhibit a rapid growth rate in the coming years due to presence of key players in the market, which are expanding their production capacity and worldwide sales. The market's growth is expected to be aided by generic medicine makers refocusing their R&D efforts on biosimilars.
The Asia pacific biopharma excipients market has been segmented on the basis of
- Solubilizers & Surfactants/Emulsifiers
- Specialty Biopharma Excipients/ Others
- Signet Chemical Corporation Pvt. Ltd.
- Sigachi Industries Pvt. Ltd.
- Meggle AG
- DFE Pharma
- SPI Pharma
- Spectrum Chemical Manufacturing Corp.
- BASF SE
Key players competing in the Asia pacific biopharma excipients market are Signet Chemical Corporation Pvt. Ltd.; ABITEC; Sigachi Industries Pvt. Ltd.; Roquette; Colorcon; Meggle AG; Clariant; DFE Pharma; SPI Pharma; IMCD; Spectrum Chemical Manufacturing Corp.; Pharmonix; BASF SE.
The market is fragmented, with a large number of local private companies capturing a large portion of the income. In order to extend their market position, established international firms are acquiring smaller players and creating relationships with local distributors. Some of the key business strategies employed by companies in this market includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.